Polymer-drug conjugation, recent achievements and general strategies

Progress in Polymer Science (Oxford)

Volumn 32, Issue 8-9, 2007, Pages 933-961

  Pasut, G ^a   Veronese, F M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Drug delivery; PEG; PEGylation; Polymer conjugation; Polymer therapeutics

Indexed keywords

COPOLYMERS; DRUG DELIVERY; ORBITAL LABORATORIES; PEPTIDES; POLYETHYLENE GLYCOLS;

IMMUNOGENICITY; PEGYLATION; POLYMER CONJUGATION; POLYMER THERAPEUTICS;

CONJUGATED POLYMERS;

EID: 34547607522     PISSN: 00796700     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.progpolymsci.2007.05.008     Document Type: Review

References (173)

1. Reddy K.R. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother 34 (2000) 915-923
2. Duncan R. Dawning era of polymer therapeutics. Nat Rev Drug Discov 2 (2003) 347-360
3. Abuchowski A., Van Es T., Palczuk N.C., and Davis F.F. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 252 (1977) 3578-3581
4. Abuchowski A., Mccoy R., Palczuk N.C., Van Es T., and Davis F.F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem 252 (1977) 3582-3586
5. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65 (2000) 271-284
6. Torchilin V.P., Voronkov J.I., and Mazoev A.V. The use of immobilized streptokinase. (Streptodekaza) for the therapy of thromboses. Ter Ark (Ther Arch Russ) 54 (1982) 21-25
7. Khandare J., and Minko T. Polymer-drug conjugates: progress in polymeric prodrugs. Progr Polym Sci 31 (2006) 359-397
8. Ringsdorf H. Structure and properties of pharmacologically active polymers. J Polym Ci Symp 51 (1975) 135-153
9. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6 (2006) 688-701
10. Langer C.J. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clin Lung Cancer 6 (2004) S85-S88
11. Sabbatini P., Brown J., Aghajanian C., Hensley M.L., Pezzulli S., O'Flaherty C., et al. A phase I/II study of PG-paclitaxel (CT-2103) in patients (pts) with recurrent ovarian, fallopian tube, or peritoneal cancer. Proc Am Soc Clin Oncol 871 (2002)
12. Kudelka A.P., Verschraegen C.F., Loyer E., Wallace S., Gershenson D.M., Han J., et al. Preliminary report of a phase I study of escalating dose PG-paclitaxel (CT-2103) and fixed dose cisplatin in patients with solid tumors. Proc Am Soc Clin Oncol 2146 (2002)
13. Langer C.J., Obyrne K., Ross H., et al. Xyotax/carboplatin vs. paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy naïve advanced non small cell lung cancer (NSCLC): the STELLAR 2 phase III study. Lung Cancer 49 Suppl 2 (2005) S36 [Abstract O-101]
14. Schoemaker N.E., van Kesteren C., Rosing H., Jansen S., Swart M., Lieverst J., et al. A phase I and pharmacokinetic study of MAG-CPT, a water soluble polymer conjugate of camptothecin. Br J Cancer 87 (2002) 608-614
15. Meerum Terwogt J.M., et al. Phase I clinical and pharmacokinetic study of PNU166945, a novel water soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 12 (2001) 315-323
16. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumouritropic accumulation of proteins and antitumour agent SMANCS. Cancer Res 25 (1986) 865-869
17. Russell-Jones G.J. The potential use of receptor-mediated endocytosis for oral drug delivery. Adv Drug Deliv Rev 20 (1996) 83-97
18. Takakura Y., Mahoto R.I., and Hashida M. Extravasation of macromolecules. Adv Drug Deliv Rev 34 (1998) 93-108
19. Okamoto C.T. Endocytosis and transcytosis. Adv Drug Deliv Rev 29 (1998) 215-228
20. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2 (2002) 750-763
21. Tomalia D.A., Baker H., Dewald J., Hall M., Kallos G., Martin S., et al. A new class of polymers-starburstdendritic macromolecules. Polym J 17 (1985) 117-132
22. Frechet J.M.J. Dendrimers and hyperbranched polymers: two families of three-dimensional macromolecules with similar but clearly distinct properties. J Macromol Sci Pure Appl Chem 33 (1996) 1399-1425
23. Frechet J.M.J., and Tomalia D.A. Dendrimers and other dendritic polymers (2001), Wiley, Chichester
24. Malefant P.R.L., and Frechet J.M.J. In: Frechet J.M.J., and Tomalia D.A. (Eds). Dendrimers and other dendritic polymers (2001), Wiley, Chichester 171-196
25. Ferruti P., Knobloch S., Ranucci E., Duncan R., and Gianasi E. A novel modification of poly(l-lysine) leading to a soluble cationic polymer with reduced toxicity and with potential as a transfection agent. Macromol Chem Phys 199 (1998) 2565-2575
26. Dautzenberg H., Zintchenko A., Konak C., Reschel T., Subr V., and Ulbrich K. Polycationic graft copolymer as carriers for oligonucleotides delivery. Complexes of oligonucleotides with polycationic graft copolymers. Langmuir 17 (2001) 3096-3102
27. Pechar M., Ulbrich K., and Subr V. Poly(ethyleneglycol) multiblock copolymers as carrier of anticancer drug doxorubicin. Bioconj Chem 11 (2000) 131-139
28. Stiriba S.E., Krautz H., and Frey H. Hyperbranched molecular nanocapsules: comparison of the hyperbranched architecture with the perfect linear analogue. J Am Chem Soc 124 (2002) 9698-9699
29. Mammen M., Choi S.K., and Whitesides G.M. Polyvalent interaction in biological system: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Edn Engl 37 (1998) 2754-2794
30. Mirhra M.K., and Kobayashi S. Star and hyperbranched polymers (1999), Marcel Dekker, Basel
31. Roy R. Recent developments in the rational design of multivalent glycoconjugates. Top Curr Chem 187 (1997) 241-274
32. Chaves F., Calvo J.C., Carvajal C., Rivera Z., Ramirez L., Pinto M., et al. Synthesis, isolation and characterization of Plasmodium falciparum antigenic tetrabranched polypeptide dendrimers obtained by thiazolidine linkages. J Pept Res 58 (2001) 307-316
33. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5 (2005) 161-171
34. Greenwald R.B. PEG drugs: an overview. J Control Release 74 (2001) 159-171
35. Pasut G., Guiotto A., and Veronese F.M. Protein, peptide and non-peptide drug PEGylation for therapeutic application: a review. Exp Opin Ther Patents 14 (2004) 859-894
36. Brocchini S., and Duncan R. In: Mathiowitz E. (Ed). Encyclopaedia of controlled drug delivery (1999), Wiley, New York 786-816
37. Kopecek J., and Bazilova H. Poly(N-(2-hydroxypropyl)methacrylamide)-1. Radical polymerisation and copolymerisation. Eur Polym J 9 (1973) 7-14
38. Lloyd J.B., Duncan R., and Pratten M.K. Soluble synthetic polymers as targetable agents for intracellular drug release. Br Polym J 15 (1983) 158-159
39. Duncan R., Kopecek J., and Lloyd J.B. Development of N-(2-hydroxypropyl)methacrylamide copolymers as carriers of therapeutic agents. In: Chiellini E., and Giusti P. (Eds). Polymers in medicine: biomedical and pharmacological applications (1983), Plenum Press, New York 97-113
40. Duncan R. Polymer therapeutics. In: Cooper E. (Ed). Business briefing pharmatech (2001), World Markets Research Centre 178-184
41. Duncan R., Cable R., Lloyd H.C., Rejmanova P., and Kopecek J. Polymers containing enzymatically degradable bonds. 7: design of oligopeptide sidechains in poly(N-(2-hydroxypropyl)methacrylamide) copolymers to promote efficient degradation by lysosomal enzymes. Makromol Chem 184 (1983) 1997-2008
42. Seymour L.W., Duncan R., Strohalm J., and Kopecek J. Effect of molecular weight of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and arte of excretion after subcutaneous, intraperitoneal and intravenous administration to rats. J Biomed Mater Res 21 (1987) 1341-1358
43. Duncan R., Kopecek J., Rejmanova P., and Lloyd J.B. Targeting of N-(2-hydroxypropyl)methacrylamide copolymers to liver by incorporation of galactose residues. Biochem Biophys Acta 755 (1983) 518-521
44. Duncan R., Coatsworth J.K., and Burtles S. Preclinical toxicology of novel polymeric antitumour agent: HPMA copolymer-doxorubicin (PK1). Hum Exp Toxicol 17 (1998) 93-104
45. Vasey P., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., et al. Phase I clinical and pharmacokinetic study of PK1 (N-(2-hydroxypropyl)methacrylamide copolymers doxorubicin): first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res 5 (1999) 83-94
46. Seymour L.W., Ferry D.R., Anderson D., Heslewood S., Julyan P.J., Poyner R., et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 20 (2002) 1668-1676
47. Gianasi E., Buckley R.G., Latigo J., Wasil M., and Duncan R. HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation. J Drug Target 10 (2002) 549-556
48. Rademaker-Lakhai J.M., Terret C., Howell S.B., Baud C.M., De Boer R.F., Pluim D., et al. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res 10 (2004) 3386-3395
49. Todd R., Sludden J., Boddy A.V., Griffin M.J., Robson L., Cassidy J., et al. Phase I and pharmacological study of CT-2103, a poly(l-glutamic acid)-paclitaxel conjugate. Proceedings of ASCO annual meeting 439 (2001)
50. Singer J.W., Baker B., de Vries P., Kumar A., Shaffer S., Vawter E., et al. Poly-(l)-glutamic acid-paclitaxel (CT-2103) [XYOTAX™], a biodegradable polymeric drug conjugate. Adv Exp Med Biol 519 (2003) 81-99
51. Cell Therapeutics. Improving Outcomes in PS2 Patients: results of the XYOTAX™ Phase III STELLAR trials. In: 11th world congress on lung cancer, Barcelona, Spain July 2005.
52. Socinski M. XYOTAX in NSCLC and other solid tumors. Emerging evidence on biological sex differences: is gender-specific therapy warranted? In: Chemotherapy Foundation XXIII symposium innovative cancer therapy for tomorrow, Mount Sinai November 2005.
53. Ross H., Bonomi P., Langer P., O'Brien M., O'Byrne K., Paz-Ares L., et al. Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaïve pts with advanced NSCLC and poor performance status (PS2). ASCO annual meeting 7039 (2006)
54. Kremer M., Judd J., Rifkin B., Auszmann J., and Oursler M.J. Estrogen modulation of osteoclast lysosomalenzyme secretion. J Cellular Biochem 57 (1995) 271-279
55. Mehvar R. Recent trends in the use of polysaccharides for improved delivery of therapeutic agents: pharmacokinetic and pharmacodynamic perspectives. Curr Pharma Biotechnol 4 (2003) 283-302
56. Danhauser-Riedl S., Hausmann E., Schick H.D., Bender R., Dietzfelbinger H., Rastetter J., et al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New Drugs 11 (1993) 187-195
57. Fujita T., Nishikawa M., Tamaki C., Takakura Y., Hashida M., and Sezaki H. Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono- and polysaccharide derivatives. J Pharmacol Exp Ther 263 (1992) 971-978
58. Elliott S., Lorenzini T., Asher S., Aoki K., Brankow D., Buck L., et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 21 (2003) 414-421
59. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Del Rev 6 (1991) 181-202
60. Maeda H., and Konno T. In: Maeda H., Edo K., and Ishida N. (Eds). Neocarzinostatin: the past, present, and future of an anticancer drug (1997), Springer, Berlin 227-267
61. Working P.K., Newman S.S., Johnson J., and Cornacoff J.B. Safety of poly(ethylene glycol) derivatives. In: Harris J.M., and Zalipsky S. (Eds). Poly(ethylene glycol) chemistry and biological applications (1997), ACS Books, Washington, DC 45-54
62. 4-acyl poly(ethylene glycol) prodrugs of ara-C: II. Efficacy in ascites and solid tumors. J Control Release 79 (2002) 55-70
63. Schiavon O., Pasut G., Moro S., Orsolini P., Guiotto A., and Veronese F.M. PEG-Ara-C conjugates for controlled release. Eur J Med Chem 39 (2004) 123-133
64. Pasut G., Scaramuzza S., Schiavon O., Mendichi R., and Veronese F.M. PEG-epirubicin conjugates with high loading. J Bioac Comp Pol 20 (2005) 213-230
65. Berna M., Dalzoppo D., Pasut G., Manunta M., Izzo L., Jones A.T., et al. Novel monodisperse PEG-dendrons as new tools for targeted drug delivery: synthesis, characterization and cellular uptake. Biomacromolecules 7 (2006) 146-153
66. Hamidi M., Azadi A., and Rafiei P. Pharmacokinetic consequences of pegylation. Drug Deliv 13 (2006) 399-409
67. Yang K., Basu A., Wang M., Chintala R., Hsieh M.C., Liu S., et al. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Prot Eng 16 (2003) 761-770
68. Israelachvili J. The different faces of poly(ethylene glycol). Proc Natl Acad Sci USA 94 (1997) 8378-8379
69. Harris J.M., and Chess R.B. Effect of PEGylation on pharmaceuticals. Nat Rev Drug Discov 2 (2003) 214-221
70. Manjula B.N., Tsai A., Updhya R., Perumalsamy K., Smith P.K., Malavalli A., et al. Site-specific PEGylation of hemoglobin at Cys-93(β): correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG Chain. Bioconjug Chem 14 (2003) 464-472
71. Basu A., Yang K., Wang M., Liu S., Chintala M., Palm T., et al. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug Chem 17 (2006) 618-630
72. Kawai F. Microbial degradations of polyethers. Appl Microbiol Biotechnol 58 (2002) 30-38
73. Mehvar R. Modulation of the pharmacokinetics and pharmacodynamic sod proteins by polyethylene glycol conjugation. J Pharm Pharm Sci 3 (2000) 125-136
74. Beranova M., Wasserbauer R., Vancurova D., Stifter M., Ocenaskova J., and Mara M. Effect of cytochrome P-450 inhibition and stimulation on intensity of polyethylene degradation in microsomial fraction of mouse and rat livers. Biomaterials 11 (1990) 521-524
75. Petrak K., and Goddard P. Transport of macromolecules across the capillary walls. Adv Drug Deliv Rev 3 (1989) 191-214
76. Yamaoka T., Tabata Y., and Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J Pharm Sci 83 (1994) 601-606
77. Yamaoka T., Tabata Y., and Ikada Y. Fate of water-soluble administered via different routes. J Pharm Sci 84 (1995) 349-354
78. Roseng L., Tolleshaug H., and Berg T. Uptake, intracellular transport, and degradation of polyethylene glicol-modified asialofetuin in hepatocytes. J Biol Chem 267 (1992) 22987-22993
79. Kratz F., Beyer U., and Schutte M.T. Drug-polymer conjugates containing acid-cleavable bonds carrier system. Crit Rev Ther Drug Carrier Syst 16 (1999) 245-288
80. Thistlethwaite A.J., Lepper D.B., Moylan D.J., and Nerlinger R.E. pH distribution in human tumors. Int J Radiat Oncol 11 (1985) 1647-1652
81. Shen W.C., and Ryser H.J.P. Cis-acconityl spacer between daunomicin and macromolecula carriers: a model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate. Biochem Byophysic Res Commun 102 (1981) 1048-1054
82. Kaneko T., Willner D., Monokovic I., Knipe J.O., Braslawsky G.R., Greenfield R.S., et al. New hydrazone derivatives of adriamycin and their immunoconjugates. A correlation between acid stability and cytotoxicity. Biocon Chem 2 (1991) 133-141
83. Coessen V., Schacht E., and Domurando D. Synthesis of polyglutamine and dextran conjugates of streptomycin with an acid-sensitive drug-carrier linkage. J Control Release 38 (1996) 141-150
84. Rejmanova P., Pohl J., Baudys M., Kostka V., and Kopecek J. Polymers containing enzimatically degradable bonds, 8: degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol Chem 184 (1984) 2009-2020
85. Greenwald R.B., Yang K., Zhao H., Conover C.D., Lee S., and Filpula D. Controlled release of proteins from their poly(ethylene glycol) conjugates: drug delivery system employing 1,6-elimination. Bioconjug Chem 14 (2003) 395-403
86. Greenwald R.B., Choe Y.H., Conover C.D., Shum K., Wu D., and Royzen M. Drug delivery systems based on trimethyl lock lactonization: poly(ethylene glycol) prodrugs of amino-containing compounds. J Med Chem 43 (2000) 475-487
87. Akiyama Y., Otsuka H., Nagasaki Y., Kato M., and Kataoka K. Selective synthesis of heterobifunctional poly(ethylene glycol) derivatives containing both mercapto and acetal terminals. Bioconjug Chem 11 (2000) 947-950
88. Zhang S., Du J., Sun R., Li X., Yang D., Zhang S., et al. Synthesis of heterobifunctional poly(ethylene glycol) with a primary amino group at one end and a carboxylate group at the other end. React Funct Polym 56 (2003) 17-25
89. Santucci L., Mencarelli A., Renga B., Pasut G., Veronese F.M., Zacheo A., et al. Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NOpegylated epirubicin. FASEB 20 (2006) 765-767
90. Rowinsky E.K., Rizzo J., Ochoa L., Takimoto C.H., Forouzesh B., Schwartz G., et al. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J Clin Oncol 21 (2003) 148-157
91. Scott L.C., Evans T., Yao J.C., Benson A.I., Mulcahy M., Thomas A.M., et al. Pegamotecan (EZ-246), a novel PEGylated camptothecin conjugate, for treatment of adenocarcinomas of the stomach and gastroesophageal (GE) junction: preliminary results of a single-agent phase 2 study. J Clin Oncology-ASCO annual meeting proceedings (Post-Meeting ed.) 22 14S July 15 Suppl (2004) 4030
92. Guiotto A., Canevari M., Orsolini P., Lavanchy O., Deuschel C., Kaneda N., et al. Synthesis, characterization, and preliminary in vivo tests of new poly(ethylene glycol) conjugates of the antitumor agent 10-amino-7-ethylcamptothecin. J Med Chem 47 (2004) 1280-1289
93. Visentin R., Pasut G., Veronese F.M., and Mazzi U. Highly efficient technetium-99m labeling procedure based on the conjugation of N-[N(3-diphenylphosphinopropionyl)glycyl]cysteine ligation with poly(ethylene glycol). Biocon Chem 15 (2004) 1046-1054
94. Veronese F.M., Schiavon O., Pasut G., Mendichi R., Andersson L., Tsirk A., et al. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Biocon Chem 16 (2005) 775-784
95. Evig C.B., Kelley E.E., Weydert C.J., Chu Y., Buettner G.R., and Burns C.P. Endogenous production and exogenous exposure to nitric oxide augment doxorubicin cytotoxicity for breast cancer cells but not cardiac myoblasts. Nitric Oxide 10 (2004) 119-129
96. Maejima Y., Adachi S., Morikawa K., Ito H., and Isobe M. Nitric oxide inhibits myocardial apoptosis by preventing caspase-3 activity via S-nitrosylation. J Mol Cell Cardiol 38 (2005) 163-174
97. Levy Y., Hershfield M.S., Fernandez-Mejia C., Polmar S.H., Scrudiery D., Berger M., et al. Adenosine deaminase deficiency with late onset or recurrent infections: response to treatment with polyethylene glycol modified adenosine deaminase. J Pediatr 113 (1988) 312-317
98. Graham L.M. PEGASPARAGINASE: a review of clinical studies. Adv Drug Deliv Rev 10 (2003) 1293-1302
99. Wang Y.S., Youngster S., Grace M., Bausch J., Bordens R., and Wyss D.F. Structural and biological characterisation of pegylated recombinant interferon α-2b and its therapeutic implications. Adv Drug Deliv Rev 54 (2002) 547-570
100. Bailon P., Palleroni A., Schaffer C.A., Spence C.L., Fung W.J., Porter J.E., et al. Rational design of a potent, long lasting form of interferon: a 40 kDa branched poly-ethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 12 (2001) 195-202
101. ®) for the treatment of hepatitis C. Adv Drug Deliv Rev 54 (2002) 571-586
102. Trainer P.J., Drake W.M., Katznelson L., Freda P.U., Herman-Bonert V., van der Lely A.J., et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342 (2000) 1171-1177
103. Kinstler O., Moulinex G., Treheit M., Ladd D., and Gegg C. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 54 (2002) 477-485
104. Na D.H., Lee K.C., and DeLuca P.P. PEGylation of octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics. Pharm Res 22 (2005) 743-749
105. Esposito P., Barbero L., Caccia P., et al. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev 55 (2003) 1279-1291
106. Bowen S., Bowen S., Tare N., et al. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp Hematol 27 (1999) 425-432
107. Eliason J.F., Greway A., Tare N., et al. Extended activity in cynomolgus monkeys of a granulocyte colony-stimulating factor mutein conjugated with high molecular weight polyethylene glycol. Stem Cells 18 (2000) 40-45
108. Chapman A.P. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 54 (2002) 531-545
109. Caliceti P., Schiavon O., Sartore L., Monfardini C., and Veronese F.M. Active site protection of proteolytic enzymes by poly(ethylene glycol) surface modification. J Bioact Biocomp Polym 8 (1993) 41-50
110. Monfardini C., Schiavon O., Caliceti P., Morpurgo M., Harris J.M., and Veronese F.M. A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug Chem 6 (1995) 62-69
111. Veronese F.M., and Morpurgo M. Bioconjugation in pharmaceutical chemistry. Farmaco 54 (1999) 497-516
112. Mokouyama E.B., Oquchi M., Kodera Y., Maeda T., and Suzuki H. Low pKa lysine residues at the active site of sarcosine oxidase from Corynebacterium sp. U-96. Biochem Biophys Res Commun 320 (2004) 846-851
113. Hinds K.D., and Kim S.W. Effects of PEG conjugation on insulin properties. Adv Drug Deliv Rev 54 (2002) 505-530
114. Yamamoto Y., Tsutsumi Y., Yoshioka Y., Nishibata T., Kobayashi K., Okamoto T., et al. Site-specific PEGylation of a lysine-deficient TNF-a with full bioactivity. Nat Biotechnol 21 (2003) 546-552
115. Zhao H., Yang K., Martinez A., Basu A., Chintala R., Liu H.C., et al. Linear and branched bicin linkers for releasable PEGylation of macromolecules: controlled release in vivo and in vitro from mono- and multi-PEGylated proteins. Bioconjug Chem 17 (2006) 341-351
116. Peleg-Shulman T., Tsubery H., Mironchik M., Fridkin M., Schreiber G., and Shechter Y. Reversible PEGylation: a novel technology to release native interferon alpha2 over a prolonged time period. J Med Chem 7 (2004) 4897-4904
117. Veronese FM, Pasut G, Tonon G, Schrepfer R. New activated poly(ethylene glycols) and related polymers and their applications. IT MI 2006A000612.
118. Pasut G., Caboi F., Schrepfer R., Tonon G., Schiavon O., and Veronese F.M. New active poly(ethylene glycol) derivative for amino coupling. React Func Polym 67 (2007) 529-539
119. Wylie D.C., Voloch M., Lee S., Liu Y.H., Cannon-Carlson S., Cutler C., et al. Carboxyalkylated histidine is a pH-dependent product of pegylation with SC-PEG. Pharm Res 18 (2001) 1354-1360
120. Wang Y.S., Youngster S., Bausch J., Zhang R., Mcnemar C., and Wyss D.F. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 39 (2000) 10634-10640
121. Hooftman G., Herman S., and Schacht E. Review: poly(ethylene glycol)s with reactive endgroups. II. Pratical consideration for the preparation of protein-PEG conjugates. J Bioact Comp Polym 11 (1996) 135-159
122. Clark R., Olson K., Fuh G., Marian M., Mortesen D., Teshima G., et al. Long-acting growth hormone produced by conjugation with polyethylene glicol. J Biol Chem 271 (1996) 21969-21977
123. Snider J., Neville C., Yuan L.-C., and Bullock J. Characterization of the heterogeneity of polyethylene glycol-modified superoxide dismutase by chromatographic and electrophoretic techniques. J Chromatogr 599 (1992) 141-155
124. Delgado C., Francis G.E., Malik F., Fisher D., and Parkes V. Polymer-derivatized proteins: analytical and preparative problems. Pharm Sci 3 (1997) 59-66
125. Snyder S.L., and Sobocinski P.Z. An improved 2,4,6-trinitrobenzenesulfonic acid method for the determination of amines. Anal Biochem 64 (1975) 284-288
126. Monkarsh S.P., Ma Y., Aglione A., Bailon P., Ciolek D., DeBarbieri B., et al. Positional isomers of mono-pegylated interferon α-2a: Isolation, characterization, and biological activity. Anal Biochem 247 (1997) 434-440
127. Veronese F.M., Sacca B., Polverido de Laureto P., Sergi M., Caliceti P., Schiavon O., et al. New PEGs for peptide and protein modification, suitable for identification of the PEGylation site. Biocon Chem 1 (2001) 62-70
128. Kubetzko S., Sarkar C.A., and Pluckthun A. Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol Pharmacol 68 (2005) 1439-1454
129. Federico R., Cona A., and Caliceti P Veronese F.M. Histaminase PEGylation: preparation and characterization of a new bioconjugate for therapeutic application. J Control Rel 115 (2006) 168-174
130. Rajan R.S., Li T., Aras M., Sloey C., Sutherland W., Arai H., et al. Modulation of protein aggregation bu polyethylene glycol conjugation: GCSF as a case study. Prot Sci 15 (2006) 1063-1075
131. Kinstler O.B., Brems D.N., Lauren S.L., Paige A.G., Hamburger J.B., and Treuheit M.J. Characterization and stability of N-terminally pegylated rhG-CSF. Pharm Res 13 (1996) 996-1002
132. He X.H., Shaw P.C., and Tam S.C. Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation. Life Sci 65 (1999) 355-368
133. Trakas N., and Tzartos N. Conjugation of acetylcholine receptor-protecting Fab fragments with polyethylene glycol results in a prolonged half-life in the circulation and reduced immunogenicity. J Neuroimmunol 120 (2001) 42-49
134. Ganson N.J., Kelly S.J., Scarlett E., Sundy J.S., and Hershfield M.S. Control of hyperuricemia in subjects with refractory gout, and induction of antibody agaist poly(ethylene glycl) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther 8 (2006) R12
135. Richter A.W., and Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol 70 (1983) 124-131
136. Cheng T.L., Cheng C.M., Chen B.M., Tsao D.A., Chuang K.H., Hsiao S.W., et al. Monoclonal antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles. Bioconjug Chem 16 (2005) 1225-1231
137. Cheng T.L., Chen B.M., Chem J.W., Wu M.F., and Roffler S.R. Efficient clearance of poly(ethylene glycol)-modified immunoenzyme with anti-PEG monoclonal antibody for prodrug cancer therapy. Bioconjug Chem 11 (2000) 258-266
138. Pasut G., and Veronese F.M. PEGylation of proteins as tailored chemistry for optimized bioconjugates. In: Satchi-Fainaro R., and Duncan R. (Eds). Advance in polymer science vol. 192 (2005), Springer, Berlin, Heidelberg 95-134
139. Veronese F.M., and Harris J.M. Introduction and overview of peptide and protein pegylation. Adv Drug Del Rev 54 (2002) 453-456
140. Balan S., Choi J.-W., Godwin A., Teo I., Laborde C.M., Heidelberger S., et al. Site-specific pegylation of protein disulfide bonds using a three-carbon bridge. Bioconjug Chem 18 (2007) 61-76
141. Veronese FM, Berna M. Novel G-CSF conjugates. Patent no. EP1737496.
142. Sato H. Enzymatic procedure for site-specific pegylation of proteins. Adv Drug Deliv Rev 54 (2002) 487-504
143. DeFrees S., Wang Z., Xing R., Scott A.E., Wang J., Zopf D., et al. GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli. Glycobiology 16 (2006) 833-843
144. Uze G., Lutfalla G., and Mongensen. Alpha and beta interferons and their friends and relations. J Interferon Cytokine Res 5 (1995) 3-26
145. Wills R.J. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 19 (1990) 390-399
146. Wong S.S. Reactive groups of proteins and their modifying agents. Chemistry of protein conjugation and cross-linking (1991), CRC Press, Boston 13
147. Piquet G., Gatti M., Barbero L., Traversa S., Caccia P., and Esposito P. Set-up of a large laboratory scale chromatographic separation of poly(ethylene glycol) derivatives of the growth hormone-releasing factor 1-29 analogue. J Chromatogr A944 (2002) 141-148
148. Goffin V., Bernichtein S., Carriere O., Bennett W.F., Kopchick J.J., and Kelly P.A. The human growth hormone antagonist B2036 does not interact with the prolactine receptor. Endocrinology 140 (1999) 3853-3856
149. Kelly S.J., Delnomdedieu M., Oliviero M.I., Williams L.D., Saifer M.G.P., Sherman M.R., et al. Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase. J Am Soc Nephrol 12 (2001) 1001-1009
150. Ishida T., Ichihara M., Wang X., Yamamoto K., Kimura J., Majima E., et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release 112 (2006) 15-25
151. Cheng P.N., Leung Y.C., Lo W.H., Tsui S.M., and Lam K.C. Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: arginase as a potential drug candidate for hepatocellular carcinoma. Cancer Lett 224 (2005) 67-80
152. Wang M., Basu A., Palm T., Hua J., Youngster S., Hwang L., et al. Engineering an arginine catabolizing bioconjugate: biochemical and pharmacological characterization of pegylated derivatives of arginine deiminase from Mycoplasma arthritidis. Bioconjug Chem 17 (2006) 1447-1459
153. Morpurgo M., Pasut G., and Veronese F.M. PEGylated proteins as cancer therapeutics. In: Torchilin V.P. (Ed). Delivery of protein and peptide drugs in cancer (2006), Imperial College Press, London 85-110
154. Veronese F.M., and Pasut G. Drug-polymers conjugates. In: Triggle D.J., and Taylor J.B. (Eds). Comprehensive medicinal chemistry II vol. 5 (2007), Elsevier, Oxford 1043-1068
155. Tuerk C., and Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249 (1990) 505-510
156. Ng E.W.M., Shima D.T., Calias P., Cunningham Jr. E.T., Guyer D.R., and Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5 (2006) 123-132
157. Ruckman J., Green L.S., Beeson J., Waugh S., Gillette W.L., Henninger D.D., et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF 165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 273 (1998) 20556-20567
158. Murad K.L., Mahany K.L., Kuypers F.A., Brugnara C., Eaton J.W., and Scott M.D. Structural and functional consequences of antigenic modulation of red cells with methoxypoly(ethylene glycol). Blood 93 (1999) 2121-2127
159. Tan Y., Qiu Y., Xu H., Ji S., Li S., Gong F., et al. Decreased immunorejection in unmatched blood transfusions by attachment of methoxypolyethylene glycol on human red blood cells and the effect on D antigen. Transfusion 46 (2006) 2122-2127
160. Scott M D., and Chen A M. Beyond the red cell: pegylation of other blood cells and tissues. Transfus Clin Biol 11 (2004) 40-46
161. Sheth S.R., and Leckband D. Measurements of attractive forces between proteins and end-grafted poly(ethylene glycol) chains. Proc Natl Acad Sci USA 94 (1997) 8399-8404
162. Mosharraf M, Malmberg M, Fransson J. Formulation, lyophilization and solid-state properties of a pegylated protein. Int J Pharmaceut 2007; doi:10.1016/j.ijpharm.2006.11.064.
163. Hermeling S., Schellekens H., Maas C., Gebbink M.F.B.G., Crommelin D.J.A., and Jiskoot W. Antibody response to aggregated human interferon alpha2b in wildtype and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci 95 (2006) 1084-1096
164. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24 (2002) 1720-1740
165. Kurre H.A., Ettinger A.G., Veenstra D.L., Gaynon P.S., Franklin J., Sencer S.F., et al. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli l-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962). J Pediatr Hematol Oncol 24 (2002) 175-181
166. Sheperd J., Brodin H.F., Cave C.B., Waugh N.R., Price A., and Gabbay J. Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Int J Technol Assess Health Care 21 (2005) 47-54
167. Bukowski R., Ernstoff M.S., Gore M.E., Nemunaitis J.J., Amato R., Gupta S.K., et al. PEGylated interferon α2b treatment for patient with solid tumors: a phase I/II study. J Clin Oncol 20 (2002) 3841-3849
168. Chapman A.P., Antoniw P., Spitali M., West S., Stephens S., and King D.J. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 17 (1999) 780-783
169. Schreiber S., Rutgeerts P., Fedorak R.N., Khaliq-Kareemi M., Kamm M.A., Boivin M., et al. CDP870 Crohn's Disease Study Group. Gastroenterology 129 (2005) 807-818
170. O'Brien M., Sandler A., Popovish A., et al. Xyotax vs. gemcitabine or vinorelbine for the treatment of performance status 2 patients with chemotherapy naive non small cell lung cancer (NSCLC): the STELLAR 4 phase III study. Lung Cancer 49 Suppl 2 (2005) S37 [Abstract O-104]
171. De Vries P, Bhatt R, Stone I, Klein P, Singer J. Optimisation of CT2106: a water soluble poly-l-glutamic acid (PG)-camptothecin conjugate with enhanced in vivo antitumor efficacy. In: Proceedings of the AACR-NCI-EORTC symposium, 2002, Miami Beach, FL.
172. Greenwald R.B., Gilbert C.W., Pendri A., Conover C.D., Xia J., and Martinez A. Drug delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J Med Chem 39 (1996) 424-431
173. 〈http://www.i-s-b.org/business/rec_sales.htm〉